Panacea Innovation Dumps Atara Shares Amid FDA Setback, Hinting at Strategic Rebalancing or Risk Mitigation—Shares Hover Near 52‑Week Low as Insider Sales Surge.
Panacea Innovation’s sale of 80,554 Atara Biotherapeutics shares amid a sharp drop signals cautious insider strategy, urging investors to monitor regulatory updates and future moves.
3 minutes to read